Please login to the form below
Youssef Bennani to chair Domain Therapeutics
He is VP R&D at Vertex
Domain Therapeutics has named Youssef Bennani as chairman of the company's board, taking over from Sam Eletr.
Bennani currently serves as site head and VP of R&D at Vertex Pharmaceuticals' site in Laval, Quebec. Prior to this, he spent seven years as VP of drug innovation at Vertex .
“Dr Bennani joins us at a time when we intend to strengthen our role as a pharma industry partner and expand our internal pipeline,” said Pascal Neuville, board director and CEO of Domain.
This pipeline includes new drug candidates targeting G protein-coupled receptors. Domain has several partnerships involving these products, including one with Merck Serono in Parkinson's disease.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Keytruda doubles five-year survival rate in NSCLC
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Taking a holistic approach to patient care
- The importance of recognising each patient as an individual...
- The concordance conundrum – the tech divide
- “Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Quick links
Infographics
